Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab/Quavonlimab + Lenvatinib in melanoma brain metastases
NCT04700072Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of quavonlimab in melanoma, sponsored by Merck & Co.. Started May 2021; status: completed.
02
Drugs
quavonlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04700072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700072.